Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · head-neck@1

ERR2278883

—

e43d5ecc-a837-589e-aa07-83a5e323c4ed

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • TNFA_SIGNALING_VIA_NFKB+0.580
  • IL6_JAK_STAT3_SIGNALING+0.520
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
  • INFLAMMATORY_RESPONSE+0.500
  • INTERFERON_GAMMA_RESPONSE+0.500
  • ANGIOGENESIS+0.490
  • INTERFERON_ALPHA_RESPONSE+0.470
  • ALLOGRAFT_REJECTION+0.440
  • KRAS_SIGNALING_UP+0.430
  • IL2_STAT5_SIGNALING+0.410

Top 10 suppressed

  • E2F_TARGETS-0.490
  • OXIDATIVE_PHOSPHORYLATION-0.480
  • MYC_TARGETS_V1-0.420
  • DNA_REPAIR-0.400
  • G2M_CHECKPOINT-0.400
  • MYC_TARGETS_V2-0.370
  • ADIPOGENESIS-0.300
  • FATTY_ACID_METABOLISM-0.270
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.150
  • MYOGENESIS-0.140

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

6 twins match this tumor's tissue · 4 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MDT-AP-3277
medullo-epn-umap@date-based
MedMedulloblastoma0.932
2MDT-AP-3156
medullo-epn-umap@date-based
MedMedulloblastoma0.916
3TCGA-AO-A03U-01B-21R-A10J-07
breast-umap@18
—D0.913
4b02dc7a2-3615-4b6c-a3dd-a866d8561d9d
colon-landscapes@1
——0.911
5TCGA-AR-A24V-01A-21R-A169-07
breast-umap@18
—A0.909
6ERR2208918
melanoma-umap@29
——0.907
7MDT-AP-2111
medullo-epn-umap@date-based
MedMedulloblastoma0.907
8SRR22247245
lung-landscapes@6
—cohortMD20.906
9MDT-AP-2743
medullo-epn-umap@date-based
MedMedulloblastoma0.905
10TCGA-CR-7376-01A-11R-2132-07
head-neck@1
——0.904

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 33 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
TNFA_SIGNALING_VIA_NFKB0.580Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.520Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.500Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.500Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.500Idelalisib— uncovered
ANGIOGENESIS0.490Remibrutinib— uncovered
INTERFERON_ALPHA_RESPONSE0.470Inavolisib— uncovered
ALLOGRAFT_REJECTION0.440Idelalisib— uncovered
KRAS_SIGNALING_UP0.430Inavolisib— uncovered
IL2_STAT5_SIGNALING0.410Idelalisib— uncovered
COMPLEMENT0.400Inavolisib— uncovered
NOTCH_SIGNALING0.350Inavolisib— uncovered
APICAL_SURFACE0.310Temsirolimus— uncovered
COAGULATION0.300Binimetinib— uncovered
TGF_BETA_SIGNALING0.300Inavolisib— uncovered
HYPOXIA0.290Idelalisib— uncovered
UV_RESPONSE_DN0.280Inavolisib— uncovered
APICAL_JUNCTION0.240Inavolisib— uncovered
ANDROGEN_RESPONSE0.210Inavolisib— uncovered
HEDGEHOG_SIGNALING0.200Inavolisib— uncovered